Study of Irinotecan and Etoposide for Lung Cancer
Author Information
Author(s): M Andol, K Eguchi, T Shinkai, T Tamura, Y Ohe, N Yamamoto, T Kurata, T Kasai, H Ohmatsu, K Kubota, I Sekine, N Hojo, T Matsumoto, T Kodama, R Kakinuma, Y Nishiwaki, N Saijo
Primary Institution: National Cancer Center Hospital
Hypothesis
Can sequential administration of irinotecan and etoposide improve treatment outcomes for metastatic non-small-cell lung cancer?
Conclusion
The sequential administration of irinotecan and etoposide resulted in severe toxicities, making the treatment regimens inappropriate for further assessment.
Supporting Evidence
- Two out of five patients in arm A achieved partial response.
- One out of four patients in arm B achieved partial response.
- Major dose-limiting toxicities included granulocytopenia and diarrhea.
Takeaway
Doctors tested two cancer drugs together to see if they could help patients with lung cancer, but the side effects were too strong to continue.
Methodology
Patients were randomly assigned to two treatment arms receiving irinotecan and etoposide in different sequences, with G-CSF support.
Limitations
The sample size was too small to detect differences in toxicities between the two arms.
Participant Demographics
{"total_patients":28,"assessable_patients":27,"age_mean":60,"sex_ratio":"16:12 male to female"}
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website